A Systematic Follow-Up of Mycobacterium tuberculosis Drug-Resistance and Associated Genotypic Lineages in the French Departments of the Americas over a Seventeen-Year Period

Table 2

Observed resistance profiles as a function of the case characteristics (new versus persistent).

Resistance profiles	New case 𝑁 (%)	Persistent 𝑁 (%)	𝑃	Total 𝑁 (%)
	𝑁𝑇=1199	𝑁𝑇=40
Resistant to INH*	84 (7,0)	9 (22,5)	0,002	93 (7,5)
Resistant to RIF*	27 (2,3)	8 (20,0)	<0,001	35 (2,8)
Resistant to EMB*	6 (0,5)	0	1,000	6 (0,5)
Resistant to SM*	66 (5,5)	1 (2,5)	0,720	67 (5,4)
Resistant to PZA*	13 (1,1)	0	1,000	13 (1,1)
Monoresistant to INH**	50 (4,2)	2 (5,0)	0,683	52 (4,2)
Monoresistant to RIF**	7 (0,6)	1 (2,5)	0,231	8 (0,7)
Monoresistant to EMB**	0	0		0
Monoresistant to SM**	40 (3,3)	1 (2,5)	1,000	41 (3,3)
Monoresistant to PZA**	4 (0,3)	0	1,000	4 (0,3)
Resistant to 1 AB***	101 (8,4)	4 (10)	0,770	105 (8,5)
Resistant to 2 AB***	32 (2,7)	7 (17,5)	<0,001	39 (3,1)
Resistant to 3 AB***	5 (0,4)	0	1,000	5 (0,4)
Resistant to 4 AB***	4 (0,3)	0	1,000	4 (0,3)

∗comprises all isolates resistant to the respective drugs (irrespective of other associated resistances).
∗∗Isolates resistant to only INH (isoniazid), RIF (rifampicin), EMB (ethambutol), SM (streptomycin), or PZA (pyrazinamide), respectively.
∗∗∗Strains resistant to 1, 2, 3, or 4 of the tested antibiotics (AB), no strain displayed resistance to all drugs.